NCT02759731View on ClinicalTrials.gov

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

June 30, 2022

Study Completion Date

May 30, 2024

Conditions

Chronic Graft vs Host DiseaseChronic Graft-Versus-Host Disease

Interventions

DRUG

Baricitinib

Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter